Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Selinexor with Chemotherapy for Relapsed Ovarian Cancer
NCT05983276Phase 2Recruiting
- Sponsor
- Loyola University Chicago
- Start
- Nov 2023
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor, decitabine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Loyola University Chicago. Started Nov 2023; status: recruiting.
02
Drugs
selinexordecitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05983276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983276.